SELLAS Life Sciences Group Cash Flow Statement
NASDAQ: SLSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
11.65+0.39 (+3.46%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
SELLAS Life Sciences Group free cash flow
In fiscal 2025, SELLAS Life Sciences Group generated -$28.4 million of operating cash flow. That left free cash flow of -$28.4 million.
Summary generated from market data by MetaCap's automated system. Methodology
SELLAS Life Sciences Group cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -26.86M | -30.88M | -37.34M | -41.30M | -20.70M | -16.76M | -19.29M | -27.67M | -23.75M | -17.68M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | — | — | — | — | — | — | — | — | — | 3.00K |
| Stock-Based Compensation | 1.96M | 1.56M | 2.09M | 1.73M | 1.01M | 578.00K | 573.00K | 395.00K | 3.17M | 354.00K |
| Change in Working Capital | -3.44M | -6.11M | 3.86M | 6.11M | -960.00K | 7.49M | -1.11M | -10.01M | 6.07M | 596.00K |
| Operating Cash Flow | -28.39M | -35.40M | -31.41M | -23.81M | -26.02M | -10.42M | -17.64M | -30.42M | -10.99M | -11.85M |
| Capital Expenditures | — | — | — | — | — | — | — | — | — | -6.00K |
| Investing Cash Flow | — | 0 | -5.50M | -4.50M | 0 | — | — | 0 | 12.16M | -85.00K |
| Dividends Paid | — | — | — | — | — | — | 0 | -487.00K | 0 | — |
| Debt Issued | — | — | — | — | — | — | — | — | — | 1.50M |
| Debt Repaid | — | — | — | — | — | — | 0 | -7.60M | -473.00K | -5.58M |
| Financing Cash Flow | 86.30M | 46.76M | 22.32M | 24.08M | 12.07M | 38.44M | 19.57M | 23.12M | 5.53M | 16.50M |
| Net Change in Cash | 57.91M | 11.36M | -14.60M | -4.23M | -13.95M | 28.02M | 1.93M | -7.30M | 6.70M | 4.57M |
| Free Cash Flow | -28.39M | -35.40M | -31.41M | -23.81M | -26.02M | -10.42M | -17.64M | -30.42M | -10.99M | -11.86M |
This table shows 10 annual periods of SELLAS Life Sciences Group's cash flow statement, from FY 2025 back to FY 2016, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow SLS's reporting calendar. What is a cash flow statement?